Literature DB >> 25769232

Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice.

A Vigolo1, A Ossato1, C Trapella2, F Vincenzi3, C Rimondo4, C Seri4, K Varani3, G Serpelloni4, M Marti5.   

Abstract

JWH-018 is a synthetic CB1 and CB2 agonist illegally marketed as products named "Spice" or "herbal blend" for its psychoactive effects which are much higher than those produced by cannabis. In the last year, the European Monitoring Centre for Drugs and Drug Addiction reported to the Italian National Early Warning System the seizure of plant material containing new halogenated derivatives of JWH-018 (JWH-018 Cl and JWH-018 Br). The present study aimed to investigate the in vitro and in vivo activity of these two new synthetic cannabinoids in mice. In vitro competition binding experiments performed on mouse and human CB1 receptors revealed a high affinity and potency of the halogenated compounds. Synthetic cannabinoids (0.01-6 mg/kg i.p.) impaired motor activity and induced catalepsy in mice and their effects were more severe with respect to those evoked by Δ(9)-THC. Moreover, they increased the mechanical and thermal pain threshold and induced a marked hypothermia. It is interesting to note that whereas high doses of JWH-018 cause seizures, myoclonia and hyperreflexia, the halogenated compounds, in particular JWH-018Br, were less effective. Behavioral and neurological changes were prevented by the selective CB1 receptor antagonist AM 251. These data demonstrate for the first time that JWH-018 Cl and JWH-018 Br act similarly to JWH-018 while inducing less convulsive episodes and myoclonias. These data support the hypothesis that the halogenated compounds may have been introduced onto market to produce similar intoxicating effects as JWH-018 while causing less side effects.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AM 251 (PubChem CID: 2125); CB(1) receptor; JWH-018; JWH-018 (PubChem CID: 10382701); JWH-018 Br; JWH-018 Cl; Synthetic cannabinoids; Δ(9)-THC; Δ(9)-THC (PubChem CID: 16078)

Mesh:

Substances:

Year:  2015        PMID: 25769232     DOI: 10.1016/j.neuropharm.2015.02.008

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  26 in total

1.  Methiopropamine and its acute behavioral effects in mice: is there a gray zone in new psychoactive substances users?

Authors:  Fabio De-Giorgio; Sabrine Bilel; Micaela Tirri; Raffaella Arfè; Claudio Trapella; Cristian Camuto; Federica Foti; Paolo Frisoni; Margherita Neri; Francesco Botrè; Matteo Marti
Journal:  Int J Legal Med       Date:  2020-05-01       Impact factor: 2.686

2.  In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors.

Authors:  Shivani Sachdev; Kiran Vemuri; Samuel D Banister; Mitchell Longworth; Michael Kassiou; Marina Santiago; Alexandros Makriyannis; Mark Connor
Journal:  Br J Pharmacol       Date:  2019-12-10       Impact factor: 8.739

Review 3.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

4.  Synthetic cannabinoids found in "spice" products alter body temperature and cardiovascular parameters in conscious male rats.

Authors:  Charles W Schindler; Benjamin R Gramling; Zuzana Justinova; Eric B Thorndike; Michael H Baumann
Journal:  Drug Alcohol Depend       Date:  2017-08-18       Impact factor: 4.492

5.  [INCREMENT]9-Tetrahydrocannabinol discriminative stimulus effects of AM2201 and related aminoalkylindole analogs in rats.

Authors:  Torbjörn U C Järbe; Roger S Gifford; Alexander Zvonok; Alexandros Makriyannis
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

6.  Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study.

Authors:  Eef L Theunissen; Nadia R P W Hutten; Natasha L Mason; Stefan W Toennes; Kim P C Kuypers; Eliza B de Sousa Fernandes Perna; Johannes G Ramaekers
Journal:  Br J Pharmacol       Date:  2017-11-29       Impact factor: 8.739

7.  Photobiomodulation Therapy Improves Acute Inflammatory Response in Mice: the Role of Cannabinoid Receptors/ATP-Sensitive K+ Channel/p38-MAPK Signalling Pathway.

Authors:  Laís M S Neves; Elaine C D Gonçalves; Juliana Cavalli; Graziela Vieira; Larissa R Laurindo; Róli R Simões; Igor S Coelho; Adair R S Santos; Alexandre M Marcolino; Maíra Cola; Rafael C Dutra
Journal:  Mol Neurobiol       Date:  2017-10-04       Impact factor: 5.590

8.  Comparison of N-methyl-2-pyrrolidone (NMP) and the "date rape" drug GHB: behavioral toxicology in the mouse model.

Authors:  Raffaella Arfè; Sabrine Bilel; Micaela Tirri; Paolo Frisoni; Giovanni Serpelloni; Margherita Neri; Federica Boccuto; Tatiana Bernardi; Federica Foti; Fabio De-Giorgio; Matteo Marti
Journal:  Psychopharmacology (Berl)       Date:  2021-04-21       Impact factor: 4.530

9.  In Vitro Metabolism and Hepatic Intrinsic Clearance of the Synthetic Cannabinoid Receptor Agonist JWH-122 and Its Four ω-Halogenated Analogues.

Authors:  Anders Bork Davidsen; Marie Mardal; Kristian Linnet
Journal:  AAPS J       Date:  2019-05-15       Impact factor: 4.009

10.  Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.

Authors:  Isabella Canazza; Andrea Ossato; Claudio Trapella; Anna Fantinati; Maria Antonietta De Luca; Giulia Margiani; Fabrizio Vincenzi; Claudia Rimondo; Fabiana Di Rosa; Adolfo Gregori; Katia Varani; Pier Andrea Borea; Giovanni Serpelloni; Matteo Marti
Journal:  Psychopharmacology (Berl)       Date:  2016-08-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.